e-Therapeutics plc Director/PDMR Shareholding (9810G)

TIDMETX

RNS Number : 9810G

e-Therapeutics plc

02 June 2017

E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Oxford, UK, 2 June 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it has today received notifications from three of its directors that they have purchased, in aggregate, 2,830,000 shares in the Company at a price of 6 pence per share. The purchases took place on 1 June 2017.

The number of ordinary shares purchased by each director is set out below:

 
 Director           Number 
                     of shares 
                     purchased 
-----------------  ----------- 
 Iain Ross           1,000,000 
-----------------  ----------- 
 Ray Barlow            830,000 
-----------------  ----------- 
 Steve Medlicott     1,000,000 
-----------------  ----------- 
 

Following these trades, the interests of those directors in ordinary shares of ETX are as follows:

 
 Director           Number       Percentage 
                     of shares    of issued 
                     held         share 
                                  capital 
-----------------  -----------  ----------- 
 Iain Ross           1,000,000        0.37% 
-----------------  -----------  ----------- 
 Ray Barlow            830,000        0.31% 
-----------------  -----------  ----------- 
 Steve Medlicott     1,250,000        0.47% 
-----------------  -----------  ----------- 
 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                      Iain Ross 
---  ------------------------  ---------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status           Non-Executive Chairman 
---  ------------------------  ---------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                      e-Therapeutics plc 
---  ------------------------  ---------------------------------- 
 b)   LEI                       21380049RHSSJXWKYT18 
---  ------------------------  ---------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ------------------------------------------------------------ 
 a)   Description of            Ordinary Shares of 0.1 pence 
       the financial 
       instrument, type          ISIN: GB00B2823H99 
       of instrument 
       Identification 
       code 
---  ------------------------  ---------------------------------- 
 b)   Nature of the             Purchase of shares 
       transaction 
---  ------------------------  ---------------------------------- 
 c)   Price(s) and              1,000,000 ordinary shares at a 
       volume(s)                 price of 6 pence per share 
---  ------------------------  ---------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  ---------------------------------- 
 e)   Date of the transaction   1 June 2017 
---  ------------------------  ---------------------------------- 
 f)   Place of the              London Stock Exchange, AIM (XLON) 
       transaction 
---  ------------------------  ---------------------------------- 
 
 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------- 
 a)   Name                      Ray Barlow 
---  ------------------------  ----------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------- 
 a)   Position/status           Chief Executive Officer 
---  ------------------------  ----------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------- 
 a)   Name                      e-Therapeutics plc 
---  ------------------------  ----------------------------------- 
 b)   LEI                       21380049RHSSJXWKYT18 
---  ------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ------------------------------------------------------------- 
 a)   Description of            Ordinary Shares of 0.1 pence 
       the financial 
       instrument, type          ISIN: GB00B2823H99 
       of instrument 
       Identification 
       code 
---  ------------------------  ----------------------------------- 
 b)   Nature of the             Purchase of shares 
       transaction 
---  ------------------------  ----------------------------------- 
 c)   Price(s) and              830,000 ordinary shares at a price 
       volume(s)                 of 6 pence per share 
---  ------------------------  ----------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  ----------------------------------- 
 e)   Date of the transaction   1 June 2017 
---  ------------------------  ----------------------------------- 
 f)   Place of the              London Stock Exchange, AIM (XLON) 
       transaction 
---  ------------------------  ----------------------------------- 
 
 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                      Steve Medlicott 
---  ------------------------  ---------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status           Finance Director 
---  ------------------------  ---------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                      e-Therapeutics plc 
---  ------------------------  ---------------------------------- 
 b)   LEI                       21380049RHSSJXWKYT18 
---  ------------------------  ---------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ------------------------------------------------------------ 
 a)   Description of            Ordinary Shares of 0.1 pence 
       the financial 
       instrument, type          ISIN: GB00B2823H99 
       of instrument 
       Identification 
       code 
---  ------------------------  ---------------------------------- 
 b)   Nature of the             Purchase of shares 
       transaction 
---  ------------------------  ---------------------------------- 
 c)   Price(s) and              1,000,000 ordinary shares at a 
       volume(s)                 price of 6 pence per share 
---  ------------------------  ---------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  ---------------------------------- 
 e)   Date of the transaction   1 June 2017 
---  ------------------------  ---------------------------------- 
 f)   Place of the              London Stock Exchange, AIM (XLON) 
       transaction 
---  ------------------------  ---------------------------------- 
 

For further information, please contact:

Contacts:

 
 e-Therapeutics plc          Tel: [phone] 
  Iain Ross, Chairman         883 125 
  Steve Medlicott, Finance    www.etherapeutics.co.uk 
  Director 
 Numis Securities Limited    Tel: +44 (0) 207 
  Michael Meade / Freddie     260 1000 
  Barnfield                   www.numis.com 
  (Corporate Finance) 
  James Black (Corporate 
  Broking) 
 Instinctif Partners         Tel: +44 (0) 207 
  Melanie Toyne Sewell /      457 2020 
  Alex Shaw                   Email: [e-mail] 
 

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

DSHLIFVDRDIFIID

(END) Dow Jones Newswires

June 02, 2017 04:00 ET (08:00 GMT)